Contact Us

Yes. SSPN rescue experiments are particularly important given its therapeutic relevance for muscular dystrophy: • Construct design: use a codon-modified SSPN sequence with a small C-terminal cytoplasmic tag (FLAG, HA). SSPN is a tetraspanin-family membrane protein — N-terminal tags can interfere with membrane topology. • Differentiation-stage-specific rescue: SSPN expression normally increases during myogenic differentiation; rescue experiments should test both proliferating myoblast and differentiated myotube contexts. • Overexpression for therapeutic studies: SSPN overexpression has been shown to ameliorate dystrophin deficiency in mouse models — rescue at supraphysiological levels is informative for therapeutic mechanism studies. • Functional readout: rescue should restore DGC component levels (β-dystroglycan, sarcoglycans) and sarcolemmal stability during myotube formation. C2C12 transduces efficiently with lentivirus and standard expression vectors; the myogenic differentiation program is preserved through standard rescue protocols, enabling staged phenotypic analysis.

The choice depends on whether you are studying SSPN's role in the dystrophin-glycoprotein complex (DGC) or modeling its emerging therapeutic potential in muscular dystrophy. The Knockout line is appropriate for asking whether SSPN is required for DGC stability, sarcolemmal integrity, or laminin binding in a muscle-relevant background. Overexpression is useful for testing SSPN's reported therapeutic effect in muscular dystrophy models — SSPN overexpression has been shown to compensate for dystrophin loss in mouse models. For muscle biology research, the EDITGENE SSPN Knockout in C2C12 is particularly relevant — C2C12 is the standard murine myoblast differentiation model, and SSPN expression increases during myogenic differentiation. Both KO and overexpression are valuable: KO reveals SSPN's contribution to DGC stability in differentiated myotubes, while overexpression tests its compensatory potential. Rescue with wild-type or domain-deletion SSPN dissects which protein regions mediate DGC stabilization.

Yes. FEM1A rescue experiments require attention to ankyrin repeat architecture: • Construct design: use a codon-modified FEM1A sequence with a small C-terminal tag (FLAG, HA). FEM1A has N-terminal ankyrin repeats (substrate recognition) and C-terminal regions — preserve all elements. • Substrate-binding-deficient rescue: ankyrin repeat mutations disrupt C-terminal degron substrate binding. • CRL2 scaffolding: rescue with FEM1A retains CRL2 complex assembly — rescue interpretation considers CUL2-elongin BC complex. • Functional readout: rescue should restore CRL2-FEM1A substrate degradation. C2C12-specific considerations: • C2C12 is a murine myoblast cell line (C3H mouse origin) — the principal continuous skeletal muscle cell model for myogenesis, muscle differentiation, and metabolic research. • Lentiviral transduction is supported with moderate efficiency; characterize myoblast markers (MyoD, Myf5) and respond to differentiation cues (low-serum medium) to drive myotube formation. • C2C12 differentiation into multinucleated myotubes is a hallmark feature useful for studying muscle-relevant gene function.

The choice depends on whether you are studying FEM1A's role as a Cullin-2 (CUL2)-RING E3 ligase substrate receptor or its functions in skeletal muscle and protein quality control. The Knockout line is the standard tool for asking whether FEM1A is required for these processes — FEM1A is one of three Fem1 family proteins (FEM1A, FEM1B, FEM1C) characterized as CRL2 (CUL2-RING ligase) substrate receptors recognizing C-terminal degron motifs (particularly C-terminal arginine-ending degrons); FEM1A has been implicated in skeletal muscle biology. Overexpression is useful for studying FEM1A gain-of-function effects. For muscle biology research, the EDITGENE Fem1a Knockout in C2C12 is highly relevant — C2C12 is a murine myoblast cell line capable of differentiating into multinucleated myotubes, providing a physiologically relevant context for skeletal muscle Fem1a study. FEM1B, FEM1C paralog expression analysis aids interpretation given functional overlap. Rescue with wild-type or substrate-binding-deficient FEM1A enables structure-function studies. The knockout is valuable for studying CRL2-FEM1A-mediated protein quality control and emerging C-terminal degron biology.

Yes. Osteopontin rescue experiments require attention to its secreted protein biology: • Construct design: use a codon-modified SPP1 sequence with a small internal or C-terminal tag (HA, FLAG). The N-terminal signal peptide for secretion and the integrin-binding RGD motif must be preserved. • RGD-deleted rescue: deletion or mutation of the RGD motif abolishes integrin binding (αvβ3, αvβ5, others) and serves as the standard control for integrin-dependent functions. • Thrombin cleavage variants: thrombin cleavage of osteopontin generates fragments with distinct activities — cleavage-resistant variants enable studying intact versus fragment functions. • Functional readout: rescue should restore secreted osteopontin levels (measured by ELISA in conditioned medium) and downstream autocrine effects on RAW 264.7 biology. RAW 264.7 is a murine macrophage cell line — transduction with lentivirus or retrovirus works at moderate efficiency; consider spinoculation for primary or suspension-like batches.

The choice depends on whether you are studying osteopontin's role in macrophage biology, bone remodeling, or its broader functions in immune regulation and cancer. The Knockout line is the standard tool for asking whether SPP1 (osteopontin) is required for macrophage-specific functions in a physiologically relevant cell context. Overexpression is useful for studying secreted osteopontin's autocrine and paracrine effects or for producing recombinant osteopontin reagents. For osteopontin research, the EDITGENE SPP1 Knockout in RAW 264.7 is highly relevant — RAW 264.7 is the standard murine macrophage cell line, and osteopontin is a major macrophage-secreted factor with established roles in osteoclast differentiation, inflammation, and tumor-associated macrophage biology. Rescue with wild-type, RGD-deleted (integrin-binding-deficient), or thrombin-cleavage-resistant osteopontin enables mechanistic dissection of its multiple functional domains.

Yes. Chchd10 rescue experiments require attention to mitochondrial intermembrane space targeting: • Construct design: use a codon-modified Chchd10 sequence with a small C-terminal tag (FLAG, HA). CHCHD10 has N-terminal MIA40-targeting signal and twin CX9C CHCH motif requiring proper disulfide bond formation in the IMS — preserve all cysteines. • IMS localization validation: confirm intermembrane space localization (proteinase K accessibility with intact outer membrane). • ALS/FTD mutation rescue: S59L, R15L, P34S, G66V mutations enable disease modeling — these mutations cause autosomal dominant gain-of-toxicity phenotypes. • Functional readout: rescue should restore mitochondrial cristae morphology; ALS mutants should recapitulate disease phenotypes. 3T3-L1-specific considerations: • 3T3-L1 is a murine preadipocyte cell line (Swiss albino mouse origin) — the principal continuous cell model for adipocyte differentiation, insulin signaling, and lipid metabolism research; can be induced to differentiate into mature adipocytes with insulin/IBMX/dexamethasone cocktail. • Lentiviral transduction is supported with moderate efficiency. • Characterize preadipocyte state and differentiation efficiency before phenotypic assays.

The choice depends on whether you are studying CHCHD10's role as a mitochondrial intermembrane space CHCHD-domain protein or modeling CHCHD10-associated ALS/FTD and other neuromuscular disorders. The Knockout line is the standard tool for asking whether CHCHD10 is required for these processes — CHCHD10 is a small intermembrane space protein with a twin CX9C motif characteristic of MIA40-imported mitochondrial proteins; CHCHD10 partners with CHCHD2 and has been characterized in mitochondrial cristae morphology, complex I assembly, and apoptosis regulation. Overexpression is useful for studying CHCHD10 in heterologous expression contexts. For neuromuscular disease research, the EDITGENE Chchd10 Knockout in 3T3-L1 enables study of Chchd10 biology in adipocyte metabolic context. CHCHD10 missense mutations (S59L, R15L, P34S, G66V, others) cause autosomal dominant amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), myopathy, Charcot-Marie-Tooth disease, and other neuromuscular disorders — CHCHD10 has emerged as a major ALS/FTD/myopathy gene. Rescue with wild-type or patient-derived CHCHD10 mutations enables disease genotype-function studies. The knockout is valuable for studying mitochondrial intermembrane space biology and CHCHD10-related neuromuscular disease mechanisms.

Yes. ZFP36L1 rescue experiments require attention to RNA-binding activity and paralog competition: • Construct design: use a codon-modified ZFP36L1 sequence. Either N- or C-terminal small tags (HA, FLAG) are tolerated; avoid large fusion tags that may interfere with RNA binding or AU-rich element recognition. • Zinc finger mutant rescue: a CCCH zinc finger RNA-binding-defective mutant is the critical specificity control for ZFP36L1 — it distinguishes phenotypes dependent on direct mRNA binding from those mediated by other protein interactions. • Paralog considerations: ZFP36L1 has functional overlap with ZFP36 (TTP) and ZFP36L2. If endogenous paralogs are expressed in MAC-T at relevant levels, rescue interpretation should account for partial functional redundancy. • Bovine-specific considerations: MAC-T is a bovine cell line; standard human/murine expression vectors are functional but bovine-codon-optimized constructs can improve expression. Lentiviral transduction works well in MAC-T with standard mammalian promoters (CMV, EF1α). • Functional readout: rescue should restore both transcriptome-wide ARE-transcript decay patterns and specific phenotypic outputs (differentiation markers, inflammatory gene expression).

The choice depends on whether you are asking what ZFP36L1 normally destabilizes in the mammary epithelial context, or whether forced ZFP36L1 expression is sufficient to drive enhanced decay of candidate ARE-containing transcripts. The Knockout line reveals the endogenous regulatory landscape — which transcripts accumulate when ZFP36L1 is absent. Overexpression tests sufficiency for accelerating decay or for outcompeting other ARE-binding proteins. For post-transcriptional regulation studies, the EDITGENE Knockout line typically gives more interpretable results because ARE-binding protein competition (with TTP, ZFP36L2) complicates overexpression readouts. Rescue experiments with wild-type or zinc finger mutant ZFP36L1 are essential for assigning observed effects to RNA-binding activity rather than other protein domains.

Yes. Dtwd1 rescue experiments in AML12 require attention to species and acp³U transferase architecture: • Construct design: use a codon-modified murine Dtwd1 sequence with a small C-terminal tag (FLAG, HA). Preserve DTW domain catalytic architecture. • Cross-species considerations: human DTWD1 can rescue murine Dtwd1 given evolutionary conservation, but species-matched rescue is preferred. • Functional readout: rescue should restore tRNA acp³U levels in hepatic tRNAs. AML12-specific considerations: • AML12 is a non-tumorigenic immortalized murine hepatocyte cell line (TGF-α transgenic CD1 mouse origin) retaining hepatocyte differentiation features. • Lentiviral transduction is supported but may require optimization. • Specialized culture conditions (DMEM/F12 with ITS-dexamethasone supplement) are required.

The choice depends on whether you are studying Dtwd1 (DTW domain containing 1)'s role as a tRNA aminocarboxypropyltransferase in murine hepatocyte context (see DTWD1/HEK293 entry for nomenclature clarification — DTWD1 is an acp³U modifier, not a pseudouridine synthase). The Knockout line is the standard tool for asking whether Dtwd1 is required for acp³U modification at tRNA position 20 in murine hepatocytes — Dtwd1 catalyzes the SAM-dependent acp³U modification, contributing to tRNA structural stability and translation fidelity. Overexpression is useful for studying Dtwd1 in heterologous expression contexts. For murine hepatic tRNA modification research, the EDITGENE Dtwd1 Knockout in AML12 is uniquely valuable — AML12 is a non-tumorigenic murine hepatocyte cell line, providing a physiologically relevant context for liver tRNA biology. This product complements the parallel DTWD1 Knockout in HEK293 (human, also available) for cross-species studies. Rescue with wild-type Dtwd1 is the standard specificity control. The knockout is valuable for studying tRNA modification biology in murine hepatic context.

Yes. TBXA2R rescue experiments require attention to GPCR topology and isoform specificity: • Construct design: use a codon-modified TBXA2R sequence with a C-terminal tag (FLAG, HA). TBXA2R is a seven-transmembrane GPCR — N-terminal tags after the signal peptide are tolerated; the third intracellular loop is critical for Gq/G12 coupling. • Isoform-specific rescue: human TPα and TPβ isoforms differ in C-terminal tails and downstream signaling — for mouse 4T1 context, ensure the rescue construct matches the studied physiology. • Signaling-deficient rescue: G-protein coupling mutations dissect ligand binding from intracellular signaling. • Functional readout: rescue should restore U46619-induced calcium mobilization and downstream signaling. 4T1 is an aggressively proliferating murine breast cancer cell line; transduction with lentivirus or retrovirus works at standard efficiency. The BALB/c-syngeneic genetic background is preserved through standard rescue protocols, enabling in vivo immune-competent xenograft studies.

The choice depends on whether you are studying TBXA2R's role in thromboxane A2 signaling in tumor cells, or its contributions to breast cancer metastasis biology. The Knockout line is appropriate for asking whether TBXA2R is required for tumor cell-intrinsic responses to thromboxane signaling — particularly relevant in 4T1, a triple-negative breast cancer model with established lung metastasis behavior. Overexpression is useful for studying whether elevated TBXA2R enhances metastatic capacity or for distinguishing TPα and TPβ isoform-specific functions. For breast cancer metastasis research, the EDITGENE TBXA2R Knockout in 4T1 is particularly valuable because 4T1 is a widely used murine syngeneic model — TBXA2R loss effects can be assessed both in vitro and in immune-competent BALB/c mice (the genetic background for 4T1). This makes the model especially relevant for studying tumor cell-intrinsic versus immune-cell-mediated contributions of TBXA2R signaling to metastasis. Rescue with wild-type or signaling-deficient TBXA2R enables mechanistic dissection.

Yes. ATP6V0D2 rescue experiments require attention to V-ATPase assembly: • Construct design: use a codon-modified Atp6v0d2 sequence with a small C-terminal tag (FLAG, HA). ATP6V0D2 is a small V0 subunit (~40 kDa) — preserve protein integrity. • V-ATPase assembly: rescue interpretation considers other V0 and V1 sector subunits for proper holoenzyme assembly. • Functional readout: rescue should restore tissue-specific V-ATPase composition and acidification. IBMDM-specific considerations: • IBMDM is an immortalized murine bone marrow-derived macrophage cell line, providing a renewable myeloid context for innate immunity and inflammasome research. • Lentiviral transduction is supported with moderate efficiency. • Macrophage activation (LPS, IFN-γ priming) should be characterized before inflammasome and antimicrobial response assays.